[go: up one dir, main page]

ATE145136T1 - Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris - Google Patents

Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris

Info

Publication number
ATE145136T1
ATE145136T1 AT90201054T AT90201054T ATE145136T1 AT E145136 T1 ATE145136 T1 AT E145136T1 AT 90201054 T AT90201054 T AT 90201054T AT 90201054 T AT90201054 T AT 90201054T AT E145136 T1 ATE145136 T1 AT E145136T1
Authority
AT
Austria
Prior art keywords
ketoconazole
retinoid
treatment
acne vulgaris
compositions
Prior art date
Application number
AT90201054T
Other languages
English (en)
Inventor
Gerard Frans Maria Cauwenbergh
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE145136T1 publication Critical patent/ATE145136T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Birds (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT90201054T 1989-05-03 1990-04-26 Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris ATE145136T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898910069A GB8910069D0 (en) 1989-05-03 1989-05-03 Method of topically treating acne vulgaris

Publications (1)

Publication Number Publication Date
ATE145136T1 true ATE145136T1 (de) 1996-11-15

Family

ID=10656092

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90201054T ATE145136T1 (de) 1989-05-03 1990-04-26 Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris

Country Status (16)

Country Link
EP (1) EP0396184B1 (de)
JP (1) JP2833711B2 (de)
KR (1) KR0161526B1 (de)
AT (1) ATE145136T1 (de)
AU (1) AU626672B2 (de)
CA (1) CA2015838C (de)
DE (1) DE69029100T2 (de)
DK (1) DK0396184T3 (de)
ES (1) ES2096577T3 (de)
GB (1) GB8910069D0 (de)
GR (1) GR3022519T3 (de)
IE (1) IE74192B1 (de)
IL (1) IL94267A (de)
PT (1) PT93935B (de)
SG (1) SG47035A1 (de)
ZA (1) ZA903339B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559149A (en) 1990-01-29 1996-09-24 Johnson & Johnson Consumer Products, Inc. Skin care compositions containing retinoids
US5583136A (en) * 1990-01-29 1996-12-10 Johnson & Johnson Consumer Products, Inc. Retinoid containing skin care compositions containing imidazoles
GB9014221D0 (en) * 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
LU87843A1 (fr) * 1990-11-15 1992-08-25 Cird Galderma Gel aqueux a base d'acide retinoique et d'hydroxypropyl-beta-cyclodextrine et son utilisation en medecine humaine et en cosmetique
GR1002207B (en) * 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
AU5955094A (en) * 1992-12-22 1994-07-19 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
ES2064288B1 (es) * 1993-07-06 1995-08-01 Ornosa Enrique Viayna Composicion para el tratamiento de afecciones cutaneas, su preparacion y su uso.
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US6150403A (en) * 1997-10-14 2000-11-21 The Procter & Gamble Company Topical compositions for regulating the oily/shiny appearance of skin
KR100247558B1 (ko) * 1997-11-24 2000-05-01 김충섭 사이클로덱스트린을 이용한 이온토포레시스 개선방법
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19943678A1 (de) * 1999-09-13 2001-03-15 Beiersdorf Ag Wirkstoffkombinationen aus oberflächenaktiven Citronensäureestern und Einschlußverbindungen von Cyclodextrinen und Retinoiden sowie kosmetische und dermatologische Zubereitungen mit einem Gehalt an solchen Gemischen
GB2365770B (en) * 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
DE10131796A1 (de) * 2001-06-30 2003-01-16 Beiersdorf Ag Verwendung von Cardiolipin in kosmetischen oder dermatologischen Zubereitungen
DE10151245A1 (de) * 2001-10-17 2003-05-15 Beiersdorf Ag Kosmetische und/oder dermatologische Wirkstoffkombination
KR100432449B1 (ko) * 2001-11-30 2004-05-22 우원홍 케토코나졸 함유 피부 미백용 외용제 조성물
FR2835434B1 (fr) * 2002-02-01 2006-03-03 Lvmh Rech Utilisation cosmetique ou dermatologique de la vitamine a ou de ses esters, en association avec une beta-cyclodextrine partiellement methylee
EP2404596A1 (de) * 2006-03-23 2012-01-11 TMRC Co., Ltd. Kit zur Krebsbehandlung und pharmazeutische Zusammensetzung zur Krebsbehandlung
WO2013107809A1 (en) * 2012-01-19 2013-07-25 Merz Pharma Gmbh & Co. Kgaa Use of azole antifungals for the treatment of actinic keratosis
CN108066342A (zh) * 2016-11-17 2018-05-25 江苏灵豹药业股份有限公司 一种复方酮康唑乳膏剂及其制备方法
CN115671285B (zh) * 2022-08-24 2024-01-05 上海市皮肤病医院 一种抗真菌溶液及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) * 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
GB2068228B (en) * 1980-01-24 1984-02-29 Janssen Pharmaceutica Nv Anti-microbial compositions for the topical treatment of acne vulgaris
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
GB2097783B (en) * 1981-04-23 1984-12-12 Dermal Lab Ltd Imidazoles
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
EP0270316A3 (de) * 1986-12-04 1989-12-06 Pfizer Inc. Topische Zusammensetzungen mit Gehalt an 1-substituierten Imidazolen und nicht-steroiden entzündungshemmenden Mitteln zur Behandlung von Akne
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients

Also Published As

Publication number Publication date
IE74192B1 (en) 1997-07-16
ZA903339B (en) 1992-01-29
IL94267A (en) 1994-11-11
PT93935A (pt) 1991-02-08
CA2015838A1 (en) 1990-11-03
IE901607L (en) 1990-11-03
KR0161526B1 (ko) 1998-12-01
DE69029100T2 (de) 1997-04-03
IL94267A0 (en) 1991-03-10
DE69029100D1 (de) 1996-12-19
JP2833711B2 (ja) 1998-12-09
GR3022519T3 (en) 1997-05-31
AU626672B2 (en) 1992-08-06
KR900017590A (ko) 1990-12-19
AU5471190A (en) 1990-11-15
EP0396184A2 (de) 1990-11-07
GB8910069D0 (en) 1989-06-21
CA2015838C (en) 2002-08-27
PT93935B (pt) 1996-11-29
ES2096577T3 (es) 1997-03-16
EP0396184B1 (de) 1996-11-13
DK0396184T3 (da) 1996-12-30
JPH02295927A (ja) 1990-12-06
SG47035A1 (en) 1998-03-20
EP0396184A3 (de) 1992-05-20

Similar Documents

Publication Publication Date Title
ATE145136T1 (de) Verwendung von ketoconazol und ein retinoid zur behandlung der akne vulgaris
ATE214933T1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
DE3752045D1 (de) Verwendung von Hydroxycarbonsäuren und Derivaten zur Herstellung topischer dermatologischer Zubereitungen zur Behandlung von Falten
ATE204704T1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69218255D1 (de) Verwendung von amino-2-trifluormethoxy-6-benzothiazol (riluzol) zur herstellung eines medikamentes zur behandlung von erkrankungen des motoneurons
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
ATE109350T1 (de) Verwendung von ofloxacin oder dessen salzen zur herstellung eines lokalpräparats für die behandlung von otopathie.
HK1004917A1 (en) L-carnitine salt and cosmetic and pharmaceutical compositions containing same for treating dermatoses
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
ATE142875T1 (de) Methode zur behandlung von haarausfall
DE69818823D1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
DE69026511D1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE3885022D1 (de) Thiosulfinsäurederivate, und die Verwendung von Thiosulfinsäurederivaten zur Herstellung von Arzneimitteln für die Behandlung von Entzündungserkrankungen.
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
HU896587D0 (en) 2-amino-carbonic acid derivatives, and medical preparations containing them as active agents, and process for the production of the active agents and the preparation
DE69022027D1 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
DE69529070D1 (de) Verwendung von 5,6-o-benzyliden-l-ascorbinsäure oder deren salze zur herstellung eines medikaments zur behandlung von hiv
DE69715227D1 (de) Verwendung von kalzium dobesilat zur herstellung eines arzneimittels zur behandlung von embryonaler zurückgebliebenheit
DE3887005D1 (de) Mittel zur Behandlung von Nierenbeschwerden.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee